<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26076014</article-id><article-id pub-id-type="pmc">4468116</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0128634</article-id><article-id pub-id-type="publisher-id">PONE-D-14-57421</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Where and When To Inject Low Molecular Weight Heparin in Hemodiafiltration? A Cross Over Randomised Trial</article-title><alt-title alt-title-type="running-head">Administration of Tinzaparin in Hemodiafiltration</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dhondt</surname><given-names>Annemieke</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Pauwels</surname><given-names>Ruben</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Devreese</surname><given-names>Katrien</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Eloot</surname><given-names>Sunny</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Glorieux</surname><given-names>Griet</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Vanholder</surname><given-names>Raymond</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Department of Nephrology, Ghent University Hospital, Ghent, Belgium</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>Coagulation Laboratory, Department of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent, Belgium</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Eller</surname><given-names>Kathrin</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Medical University of Graz, AUSTRIA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: AD. Performed the experiments: AD RP. Analyzed the data: AD RP KD SE GG RV. Wrote the paper: AD RP KD SE GG RV.</p></fn><corresp id="cor001">* E-mail: <email>annemie.dhondt@ugent.be</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>6</issue><elocation-id>e0128634</elocation-id><history><date date-type="received"><day>2</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>27</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Dhondt et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Dhondt et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0128634.pdf"/><abstract><sec id="sec001"><title>Background and Objective</title><p>Low molecular weight heparins (LMWHs) are small enough to pass large pore dialysis membranes. Removal of LMWH if injected before the start of the session is possible during high-flux dialysis and hemodiafiltration. The aim of this study was to determine the optimal mode (place and time) of tinzaparin administration during postdilution hemodiafiltration.</p></sec><sec id="sec002"><title>Study Design, Setting, Patients</title><p>In 13 chronic hemodiafiltration patients, 3 approaches of injection were compared in a randomised cross over trial: i) before the start of the session at the inlet blood line filled with rinsing solution (IN<sub>0</sub>), ii) 5 min after the start at the inlet line filled with blood (IN<sub>5</sub>) and iii) before the start of the session at the outlet blood line (OUT<sub>0</sub>). Anti-Xa activity, thrombin generation, visual clotting score and reduction ratios of urea and beta2microglobulin were measured.</p></sec><sec id="sec003"><title>Results</title><p>Anti-Xa activity was lower with IN<sub>0</sub> compared with IN5 and OUT<sub>0</sub>, and also more thrombin generation was observed with IN<sub>0</sub>. No differences were observed in visual clotting scores and no clinically relevant differences were observed in solute reduction ratio. An anti-Xa of 0.3 IU/mL was discriminative for thrombin generation. Anti-Xa levels below 0.3 IU/mL at the end of the session were associated with worse clotting scores and lower reduction ratio of urea and beta2microglobulin.</p></sec><sec id="sec004"><title>Conclusions</title><p>Injection of tinzaparin at the inlet line before the start of postdilution hemodiafiltration is associated with loss of anticoagulant activity and can therefore not be recommended. Additionally, we found that an anti-Xa above 0.3 IU/mL at the end of the session is associated with less clotting and higher dialysis adequacy.</p></sec><sec id="sec005"><title>Trial Registration</title><p>Clinicaltrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=NCT00756145">NCT00756145</ext-link>
</p></sec></abstract><funding-group><funding-statement>The authors received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="3"/><page-count count="13"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec006"><title>Introduction</title><p>For renal replacement strategies such as hemodialysis and hemodiafiltration, anticoagulants are required to prevent clotting of the extracorporeal circuit. Over-anticoagulation can be associated with hemorrhage and prolonged bleeding at the needle insertion sites. Insufficient inhibition of the coagulation cascade can lead to premature interruption of the dialysis session. More subtle under-anticoagulation could lead to clotting of some fibers with a decrease in membrane exchange surface area eventually resulting in a reduction in dialysis efficiency.</p><p>Low molecular weight heparins (LMWH) are often preferred to unfractionated heparin [<xref rid="pone.0128634.ref001" ref-type="bibr">1</xref>] because of the ease of a single injection at the start of the session; they are widely used anticoagulants for hemodialysis [<xref rid="pone.0128634.ref002" ref-type="bibr">2</xref>]. LMWHs have mean molecular weights (MW) between 3600 and 6500 D. Therefore, especially if unbound, they can pass high-flux dialysis membranes. So when LMWHs are administered at the inlet blood line before the lines are filled with blood, they may disappear in the dialysate compartment. Tinzaparin is a LMWH obtained by enzymatic depolymerization of unfractionated heparin. The mean MW of the chains is 6500 D.</p><p>The aim of this study was to determine the optimal mode of administration of LMWH as anticoagulant during postdilution hemodiafiltration.</p><p>Three approaches of administration of tinzaparin were compared: i) before the start of the session at the inlet blood line filled with rinsing solution (IN<sub>0</sub>), ii) 5 min after the start of the session at the inlet blood line filled with blood (IN<sub>5</sub>) and iii) before the start of the session at the outlet blood line (OUT<sub>0</sub>). Anti-Xa levels, thrombin generation, visual appreciation of clotting of the circuit and dialysis performance measured as RR of a small and middle MW molecule were considered.</p></sec><sec sec-type="materials|methods" id="sec007"><title>Materials and Methods</title><sec id="sec008"><title>Study design</title><p>The protocol for this trial and supporting CONSORT checklist are available as supporting information; see <xref rid="pone.0128634.s007" ref-type="supplementary-material">S1</xref>&#x02013;<xref rid="pone.0128634.s009" ref-type="supplementary-material">S3</xref> Texts. The study flow chart of this cross over randomised trial is summarized in <xref rid="pone.0128634.g001" ref-type="fig">Fig 1</xref>. In each patient, three options were studied in cross over: i) administration of tinzaparin at the inlet blood line just before the start of the blood pump (IN<sub>0</sub>), ii) administration at inlet blood line 5 minutes after the detection of blood by the blood detector (IN<sub>5</sub>) and iii) administration at the outlet blood line just prior the start of the blood pump (OUT<sub>0</sub>). The dose of tinzaparin remained unchanged throughout the study. The sequence of the sessions per patient was assigned randomly. For each patient, the experimental sessions were performed with a 1-week interval at the same dialysis day of the week, either first, second, or third session of the week. Blood was sampled from the vascular access at the start of the session, before heparin injection and from the inlet dialyzer blood line at times 10, 30, 120, 180 and 240 min. Also transmembrane pressure (TMP), prefilter pressure, pressure in inlet and outlet bloodline were registered at 10, 30, 60, 90, 120, 150, 180, 210 and 240 min. Primary end-point was the anti-Xa activity at the end of the session. Secondary end-points were: anti-Xa activity at the start, after 30, 120 and 180 min, ETP at the start and after 30, 120, 180 and 240 min, dialysis efficiency measured as reduction ratio of urea and beta2microglobulin after 10, 180 and 240 min. Other secondary end-points were visual clotting scores at the end of the session and pressure measurements along the circuit.</p><fig id="pone.0128634.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128634.g001</object-id><label>Fig 1</label><caption><title>Study flow chart: generation of allocation sequence, enrollment and assignment was done by AD.</title></caption><graphic xlink:href="pone.0128634.g001"/></fig></sec><sec id="sec009"><title>Patients</title><p>Fourteen patients treated with chronic hemodiafiltration at the Ghent University Hospital were included in the study from september 2008 until march 2010 (<xref rid="pone.0128634.g001" ref-type="fig">Fig 1</xref>). Inclusion criteria were chronic kidney disease stade V, older than 18 years and hematocrit above 30%. Exclusion criteria for the study were: active bleeding, infection or malignancy, hepatic failure, thrombocytopenia below 120,000/&#x003bc;L, treatment with vitamin K antagonists, administration of heparin or anticoagulants for other reasons than anticoagulation for dialysis, allergy towards heparin. Thirteen chronic hemodialysis patients (8 males, 5 females, median age 74 years (69&#x02013;80 interquartile range)), completed the study. One patient was prematurely excluded due to an unrelated infectious adverse event. The median and interquartile range of body weight was 68 (63&#x02013;81.5) kg. The renal diagnoses were diabetic nephropathy (n = 4), renal vascular disease (n = 3), chronic interstitial kidney disease (n = 2), and other (n = 4). As dialyis anticoagulant, tinzaparin (Innohep, Leo Pharmaceutical Corp, Ballerup, Denmark), with median and interquartile range of 4500 (3500&#x02013;4500) IU was routinely used. Before the study, tinzaparin was injected in the afferent blood line shortly after the start of the session. The doses had been defined prior to the start of the study, based on the presence or absence of visible clotting of membrane and circuit and/or prolonged bleeding after dialysis.</p><p>Four patients received antiplatelet therapy, either aspirin (n = 3) and/or clopidogrel (n = 2). Residual renal function measured as average of creatinine and urea clearance was 3.0 (0&#x02013;5.2) mL/min.</p></sec><sec id="sec010"><title>Ethics statement</title><p>Approval of the local ethics committee (Ghent University Hospital ethics committee) was obtained, as well as written informed consent of all patients. The study was registered in clinicaltrials.gov as NCT00756145.</p></sec><sec id="sec011"><title>Hemodiafiltration</title><p>The hemodiafiltration treatments were performed with AK200 ULTRA S (Gambro, Lund, Sweden) dialysis machines with BL200BD and BL208BD (Gambro, Medolla, Italy) as inlet and outlet blood lines. As dialyzer, single use Helixone membranes (FX800, Fresenius Medical Care, Bad Homburg, Germany) were used. No heparin was added in the rinsing solution of the circuit.</p><p>As anticoagulant, prefilled syringes containing tinzaparin were used in the same dose as before the study. The hemodiafiltration sessions lasted 240 minutes with the following characteristics: effective blood flow 300 mL/min, dialysate flow 600 mL/min, volume controlled postdilution hemodiafiltration with an effective convection rate of 75 mL/min.</p><p>During the sessions no other intravenous medication was administered.</p><p>At the end of the session, the circuit was rinsed by means of an online restitution program.</p></sec><sec id="sec012"><title>Sample collection</title><p>Blood samples were collected in citrated tubes (Venosafe 3.6 ml, 0.109 M buffered sodium citrate, Terumo Europe, Leuven, Belgium) for measurement of anti-Xa, antithrombin and thrombin generation; in tubes with gel and clotting activator (VenosafeAutosep, Terumo) for CRP, urea and beta2microglobulin and in K-EDTA tubes (BD Plymouth, UK) for hematocrit.</p><p>Hematocrit and CRP were measured immediately; serum and plasma samples for all other determinations were kept at &#x02212;80&#x000b0;C for further analysis.</p></sec><sec id="sec013"><title>Analytical techniques</title><p>CRP was measured through a particle enhanced immunoturbidimetric assay (CRPLX, Roche Diagnostica, Mannheim, Germany).</p><p>Hematocrit was determined by centrifugation (Heraus Centrifuge, Labofuge 400).</p><p>Beta2microglobulin concentrations were quantified using an ELISA kit (Orgentec Diagnostika GmbH, Mainz, Germany) and an EL808 Ultramicroplate Reader (Bio-Tek Instruments, Winooski, VT, USA).</p><p>Urea was measured by a standard laboratory method on Roche Cobas 6000 chemistry analyzer (Roche Diagnostics).</p><p>Anti-Xa activity was measured by a chromogenic method (Biophen Heparin, Hyphen BioMed, Neuville-sur-Oise, France) on a STA-C (Diagnostica Stago, Asni&#x000e8;res, France) with detection limit 0.05 IU/mL.</p><p>Analysis of antithrombin was carried out using a chromogenic method (Coamatic Antithrombin, Chromogenix, Instrumentation Laboratory, Milan, Italy).</p><p>Automated measurement of thrombin generation was performed by Calibrated Automated Thrombography (Thrombinoscope, Maastricht, The Netherlands), as reported previously [<xref rid="pone.0128634.ref003" ref-type="bibr">3</xref>]. Thrombin generation was triggered in platelet-poor plasma in the presence of 5 pM tissue factor and a concentration of 4 &#x003bc;M phospholipids. Measurements were performed in duplicate and reported as endogenous thrombin potential (ETP), being the area under the curve of thrombin generation over time. Values were normalized by dividing the patient sample result by the result of a pooled plasma from 50 healthy donors analyzed in the same run.</p></sec><sec id="sec014"><title>Other parameters</title><p>Transmembrane pressure (TMP), prefilter pressure, pressure in inlet and outlet bloodline as well as hemoconcentration measured by blood volume sensor (BVS) were registered at 10, 30, 60, 90, 120, 150, 180, 210 and 240 min.</p><p>At the end of the session, immediately after blood restitution, visual clotting score of membrane, blood lines, expansion chamber and bubble trap were rated by two unblinded investigators (AD and RP). They rated independently, followed by consensus. The clotting score of the membrane was as follows: 0 = no clotting, 1 = a few colored fibers, 2 = less than 50% of the visible fibers colored and 3 = more than 50% of fibers colored. Clotting of blood lines, expansion chamber and bubble trap was scored as: 0 = no clotting, 1 = discoloration, 2 = minimal clot, 3 = major clot.</p><p>Applied compression time was registered.</p></sec><sec id="sec015"><title>Calculations and statistics</title><p>Sample size was set at 14, based on feasibility. No prior data on anti-Xa activity in this setting were available to calculate sample size.</p><p>The sequence of the sessions per patient was randomized by Quick Calcs (Graphpad software), an online computer system which generates a random number sequence based on the number of experimental groups. The allocation was not concealed.</p><p>Reduction ratio (RR), concentration at different time points (Ct after 10, 180 and 240 min) versus the start of dialysis (C0) expressed in %, was calculated as:
<disp-formula id="pone.0128634.e001"><alternatives><graphic xlink:href="pone.0128634.e001.jpg" id="pone.0128634.e001g" position="anchor" mimetype="image" orientation="portrait"/><mml:math id="M1"><mml:mrow><mml:mtext>RR&#x000a0;</mml:mtext><mml:mo>=</mml:mo><mml:mtext>&#x000a0;</mml:mtext><mml:mn>100</mml:mn><mml:mtext>&#x000a0;X</mml:mtext><mml:mo>&#x000a0;</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#x000a0;</mml:mo><mml:mo>&#x02013;</mml:mo><mml:mo>&#x000a0;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(1)</label></disp-formula>
</p><p>Concentrations of beta2microglobulin were corrected for hemoconcentration as measured by BVS:
<disp-formula id="pone.0128634.e002"><alternatives><graphic xlink:href="pone.0128634.e002.jpg" id="pone.0128634.e002g" position="anchor" mimetype="image" orientation="portrait"/><mml:math id="M2"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mrow/><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mtext>X&#x000a0;</mml:mtext><mml:mn>100</mml:mn><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>100</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mtext>BVS</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives><label>(2)</label></disp-formula>
</p><p>Delta TMP was calculated as the measured TMP at 240 min minus the TMP measured at 10 min. Data are expressed as median and interquartile ranges. Statistics and figures were generated with SPSS (SPSS Inc., Chicago, IL) and GraphPad Prism 4.0 (GraphPad Software, San Diego, California). Continuous paired data were analyzed with repeated measures analysis of variance (Friedman) followed by Wilcoxon in case of significance. Chi square test was performed for categorical variables. Correlations were tested with Spearman correlation test. Receiver Operator Characteristic (ROC) analysis was applied to determine cut off values of anti-Xa. Significance was accepted if p&#x0003c;0.05.</p></sec><sec id="sec016"><title>Deviation from initial protocol</title><p>Initially we intended to measure clearances for urea and beta2microglobulin as measure of dialysis efficiency. This was however not feasible due to the important interference of the decrease in bloodwaterflow due to ultrafiltration. Hence dialysis efficiency was expressed as reduction ratio of urea and beta2microglobulin.</p><p>Primary and secondary end-points were initially ill-defined; a shift towards secondary end-points with only one primary end-point left was made.</p><p>Patient N&#x000b0; 5 received his second experimental session (IN<sub>0</sub>) 2 days later than planned because of a technical problem.</p><p>Initially we intended to have 14 patients completing the study. Due to feasibility issues we did not replace patient N&#x000b0; 4 (after his exclusion from the study due to infection). So we ended up with 13 patients completing the study.</p></sec></sec><sec sec-type="results" id="sec017"><title>Results</title><p>The median and interquartile range of the administered dose of tinzaparin was 66.0 (54.5&#x02013;69.8) IU/kg body weight (<xref rid="pone.0128634.s001" ref-type="supplementary-material">S1 Fig</xref>). No premature interruptions of the sessions or bleeding occurred.</p><p>In <xref rid="pone.0128634.t001" ref-type="table">Table 1</xref>, predialysis values of hematocrit, antithrombin and CRP are shown as well as ultrafiltration and substitution volumes and fistula compression times. No differences between the 3 schedules were observed.</p><table-wrap id="pone.0128634.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128634.t001</object-id><label>Table 1</label><caption><title>Predialysis hematocrit, antithrombine, CRP and applied volumes and compression times: median and interquartile range.</title></caption><alternatives><graphic id="pone.0128634.t001g" xlink:href="pone.0128634.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">IN<sub>0</sub>
</th><th align="left" rowspan="1" colspan="1">IN<sub>5</sub>
</th><th align="left" rowspan="1" colspan="1">OUT<sub>0</sub>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hematocrit (%)</td><td align="left" rowspan="1" colspan="1">36 (35&#x02013;39)</td><td align="left" rowspan="1" colspan="1">36 (35&#x02013;39)</td><td align="left" rowspan="1" colspan="1">37 (34&#x02013;38)</td></tr><tr><td align="left" rowspan="1" colspan="1">Antithrombin (%)</td><td align="left" rowspan="1" colspan="1">97 (92&#x02013;112)</td><td align="left" rowspan="1" colspan="1">97 (86&#x02013;99)</td><td align="left" rowspan="1" colspan="1">93 (86&#x02013;113)</td></tr><tr><td align="left" rowspan="1" colspan="1">CRP (mg/L)</td><td align="left" rowspan="1" colspan="1">3 (1&#x02013;7)</td><td align="left" rowspan="1" colspan="1">3 (2&#x02013;6)</td><td align="left" rowspan="1" colspan="1">2 (2&#x02013;11)</td></tr><tr><td align="left" rowspan="1" colspan="1">Ultrafiltered volume (L)</td><td align="left" rowspan="1" colspan="1">1.65 (0.79&#x02013;1.88)</td><td align="left" rowspan="1" colspan="1">1.69 (0.86&#x02013;2.42)</td><td align="left" rowspan="1" colspan="1">1.39 (0.79&#x02013;2.38)</td></tr><tr><td align="left" rowspan="1" colspan="1">Substitution volume (L)</td><td align="left" rowspan="1" colspan="1">15.8 (15.2&#x02013;16.3)</td><td align="left" rowspan="1" colspan="1">15.7 (14.8&#x02013;16.4)</td><td align="left" rowspan="1" colspan="1">16.1 (15.6&#x02013;16.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Applied compression time inlet needle (min)</td><td align="left" rowspan="1" colspan="1">16 (13&#x02013;18)</td><td align="left" rowspan="1" colspan="1">15 (13&#x02013;16)</td><td align="left" rowspan="1" colspan="1">15 (9&#x02013;18)</td></tr><tr><td align="left" rowspan="1" colspan="1">Applied compression time outlet needle (min)</td><td align="left" rowspan="1" colspan="1">14 (9&#x02013;16)</td><td align="left" rowspan="1" colspan="1">12 (9&#x02013;16)</td><td align="left" rowspan="1" colspan="1">14 (7&#x02013;14)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Abbreviations: IN<sub>0</sub>: tinzaparin injection before the start of the session at the inlet blood line; IN<sub>5</sub>: injection 5 min after the start of the session at the inlet blood line and OUT<sub>0</sub>: injection before the start of the session at the outlet blood line; C Reactive Protein (CRP.)</p></fn><fn id="t001fn002"><p>Comparison between schedules: no significant differences.</p></fn></table-wrap-foot></table-wrap><sec id="sec018"><title>Coagulation parameters</title><sec id="sec019"><title>Anti-Xa activity</title><p>The evolution of anti-Xa activity is displayed in <xref rid="pone.0128634.t002" ref-type="table">Table 2</xref> and <xref rid="pone.0128634.s002" ref-type="supplementary-material">S2 Fig</xref> Predialysis anti-Xa activity was consistently zero. The highest values were measured at 30 min, followed by a gradual decrease. When comparing the different schedules, the lowest anti-Xa activity was measured during the sessions with administration of tinzaparin at the inlet blood line before the start (IN<sub>0</sub>). No differences in anti-Xa levels were observed between IN<sub>5</sub> and OUT<sub>0</sub>.</p><table-wrap id="pone.0128634.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128634.t002</object-id><label>Table 2</label><caption><title>Anti-Xa activity: median and interquartile range.</title></caption><alternatives><graphic id="pone.0128634.t002g" xlink:href="pone.0128634.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">IN<sub>0</sub>
</th><th align="left" rowspan="1" colspan="1">IN<sub>5</sub>
</th><th align="left" rowspan="1" colspan="1">OUT<sub>0</sub>
</th><th align="left" rowspan="1" colspan="1">Comparison between schedules: <italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Pre</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">30 min</td><td align="left" rowspan="1" colspan="1">0.95 (0.88&#x02013;1.27)</td><td align="left" rowspan="1" colspan="1">1.13 (1.06&#x02013;1.33)</td><td align="left" rowspan="1" colspan="1">1.12 (0.89&#x02013;1.37)</td><td align="left" rowspan="1" colspan="1">IN<sub>0</sub> vs IN<sub>5</sub>:0.01IN<sub>0</sub> vs OUT<sub>0</sub>:0.094 IN<sub>5</sub> vs OUT<sub>0</sub>:0.37</td></tr><tr><td align="left" rowspan="1" colspan="1">120 min</td><td align="left" rowspan="1" colspan="1">0.65 (0.46&#x02013;0.97)</td><td align="left" rowspan="1" colspan="1">0.77 (0.56&#x02013;0.97)</td><td align="left" rowspan="1" colspan="1">0.74 (0.57&#x02013;1.07)</td><td align="left" rowspan="1" colspan="1">IN<sub>0</sub> vs IN<sub>5</sub>:&#x0003c;0.001IN0 vs OUT<sub>0</sub>:0.003IN<sub>5</sub> vs OUT<sub>0</sub>:0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">180 min</td><td align="left" rowspan="1" colspan="1">0.34 (0.25&#x02013;0.75)</td><td align="left" rowspan="1" colspan="1">0.50 (0.34&#x02013;0.78)</td><td align="left" rowspan="1" colspan="1">0.47 (0.29&#x02013;0.85)</td><td align="left" rowspan="1" colspan="1">IN<sub>0</sub> vs IN<sub>5</sub>:0.01IN<sub>0</sub> vs OUT<sub>0</sub>:0.01IN<sub>5</sub> vs OUT<sub>0</sub>:0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">240 min</td><td align="left" rowspan="1" colspan="1">0.14 (0.09&#x02013;0.45)</td><td align="left" rowspan="1" colspan="1">0.24 (0.17&#x02013;0.60)</td><td align="left" rowspan="1" colspan="1">0.25 (0.15&#x02013;0.64)</td><td align="left" rowspan="1" colspan="1">IN<sub>0</sub> vs IN<sub>5</sub>:&#x0003c;0.001IN<sub>0</sub> vs OUT<sub>0</sub>:&#x0003c;0.001IN<sub>5</sub> vs OUT<sub>0</sub>:0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Comparison between time points: <italic>p</italic>
</td><td align="left" rowspan="1" colspan="1">Between all time points: 0.001</td><td align="left" rowspan="1" colspan="1">Pre vs 240 min: 0.002Between all other time points: 0.001</td><td align="left" rowspan="1" colspan="1">Between all time points: 0.001</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Abbreviations: IN<sub>0</sub>: tinzaparin injection before the start of the session at the inlet blood line; IN<sub>5</sub>: injection 5 min after the start of the session at the inlet blood line and OUT<sub>0</sub>: injection before the start of the session at the outlet blood line.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec020"><title>Endogenous thrombin potential (ETP)</title><p>The evolution of ETP is presented in <xref rid="pone.0128634.t003" ref-type="table">Table 3</xref>. ETP decreased from normal values predialysis to zero at 30 and 120 min. After 180 and 240 min ETP was again detected in 8 and 21 out of 39 sessions, respectively. When tinzaparin was administered at the inlet line before the start (IN<sub>0</sub>), a higher ETP was observed compared to the sessions where tinzaparin was administered after 5 min (IN<sub>5</sub>) or at the outlet line (OUT<sub>0</sub>).</p><table-wrap id="pone.0128634.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128634.t003</object-id><label>Table 3</label><caption><title>Endogenous Thrombin Potential (ETP): median and interquartile range.</title></caption><alternatives><graphic id="pone.0128634.t003g" xlink:href="pone.0128634.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">IN<sub>0</sub>
</th><th align="left" rowspan="1" colspan="1">IN<sub>5</sub>
</th><th align="left" rowspan="1" colspan="1">OUT<sub>0</sub>
</th><th align="left" rowspan="1" colspan="1">Comparison between schedules: <italic>p</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Pre</td><td align="left" rowspan="1" colspan="1">0.96 (0.84&#x02013;1.16)</td><td align="left" rowspan="1" colspan="1">0.97 (0.88&#x02013;1.12)</td><td align="left" rowspan="1" colspan="1">0.97 (0.86&#x02013;1.14)</td><td align="left" rowspan="1" colspan="1">IN<sub>0</sub> vs IN<sub>5</sub>:0.19IN<sub>0</sub> vs OUT<sub>0</sub>:0.94IN<sub>5</sub> vs OUT<sub>0</sub>:0.50</td></tr><tr><td align="left" rowspan="1" colspan="1">30 min</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">120 min</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">180 min</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;0.07)</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="left" rowspan="1" colspan="1">0 (0&#x02013;0)</td><td align="left" rowspan="1" colspan="1">IN<sub>0</sub> vs IN<sub>5</sub>:0.062IN<sub>0</sub> vs OUT<sub>0</sub>:0.19IN<sub>5</sub> vs OUT<sub>0</sub>:1</td></tr><tr><td align="left" rowspan="1" colspan="1">240 min</td><td align="left" rowspan="1" colspan="1">0.39 (0&#x02013;0.60)</td><td align="left" rowspan="1" colspan="1">0.06 (0&#x02013;0.17)</td><td align="left" rowspan="1" colspan="1">0.01 (0&#x02013;0.09)</td><td align="left" rowspan="1" colspan="1">IN<sub>0</sub> vs IN<sub>5</sub>:0.031IN<sub>0</sub> vs OUT<sub>0</sub>:0.039IN<sub>5</sub> vs OUT<sub>0</sub>:0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">Comparison between time points: <italic>p</italic>
</td><td align="left" rowspan="1" colspan="1">Pre vs all time points: &#x0003c;0.00130 and 120 min vs 180 min: 0.04330 and 120 min vs 240 min: 0.018180 vs 240 min: 0.016</td><td align="left" rowspan="1" colspan="1">Pre vs all time points: &#x0003c;0.00130 and 120 min vs 180 min: 0.1830 and 120 min vs 240 min: 0.018180 vs 240 min: 0.016</td><td align="left" rowspan="1" colspan="1">Pre vs all time points: &#x0003c;0.00130 and 120 min vs 180 min: 0.3230 and 120 min vs 240 min: 0.018180 vs 240 min: 0.016</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>Abbreviations: IN<sub>0</sub>: tinzaparin injection before the start of the session at the inlet blood line; IN<sub>5</sub>: injection 5 min after the start of the session at the inlet blood line and OUT<sub>0</sub>: injection before the start of the session at the outlet blood line.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec021"><title>Visual clotting scores</title><p>Visual clotting score of blood lines was consistently scored 0 for all sessions. Visual clotting scores of membrane, expansion chamber and bubble trap were not different in the three administration schedules (<xref rid="pone.0128634.s003" ref-type="supplementary-material">S3 Fig</xref>).</p></sec><sec id="sec022"><title>Relationship between clotting parameters</title><p>The relation between ETP and anti-Xa activity can be appreciated from <xref rid="pone.0128634.g002" ref-type="fig">Fig 2</xref>. When anti-Xa activity is zero, ETP is present. As soon as anti-Xa rises above 0.3 IU/mL, ETP is undetectable. With an anti-Xa value below 0.3 IU/mL, a gradual increase in ETP is observed with decreasing anti-Xa.</p><fig id="pone.0128634.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128634.g002</object-id><label>Fig 2</label><caption><title>Endogenous thrombin potential (ETP) in relation to anti-Xa activity.</title></caption><graphic xlink:href="pone.0128634.g002"/></fig><p>Using ROC analysis, an anti-Xa activity of 0.3 IU/mL was able to discriminate for detectable ETP with a sensitivity and specificity of 0.953 and 0.985, respectively (area under the ROC curve of 0.996 with 95% confidence interval: 0.99&#x02013;1.00).</p><p>When evaluating the visual clotting score of the membrane, bubble trap and expansion chamber in function of anti-Xa activity at the end of the session, severe clotting (score 3) was not observed in patients with residual anti-Xa activity above 0.3 IU/mL at the end of the session (<xref rid="pone.0128634.s004" ref-type="supplementary-material">S4 Fig</xref>). When comparing visual clotting scores in patients with a residual anti-Xa activity below versus above 0.3 IU/mL, a significantly higher clotting score of bubble trap and expansion chamber was observed in those with anti-Xa below 0.3 IU/mL (p&#x0003c;0.001 and p = 0.012, respectively). When comparing visual clotting scores in patients with or without ETP at 240 min, also a higher clotting score of bubble trap and expansion chamber was observed in patients with ETP (p&#x0003c;0.001 and p = 0.014, respectively).</p></sec></sec><sec id="sec023"><title>Pressure measurement</title><sec id="sec024"><title>Transmembrane pressure (TMP)</title><p>TMP increased during the session from 53 (48&#x02013;57) mmHg at 10 min to 85 (78&#x02013;104) at 240 min (p&#x0003c;0.001) for IN<sub>0</sub>, from 52 (47&#x02013;56) to 79 (70&#x02013;99) for IN<sub>5</sub> (p&#x0003c;0.001) and from 54 (48&#x02013;57) to 90 (77&#x02013;103) mmHg for OUT<sub>0</sub> (p&#x0003c;0.001). No differences were observed between the three groups, neither at 10 nor at 240 min.</p><p>The increase in TMP at the end of the session expressed as delta TMP was not different between the three administration schedules being 37 (31&#x02013;48), 27 (22&#x02013;42) and 38 (24&#x02013;49) mmHg for IN<sub>0</sub>, IN<sub>5</sub> and OUT<sub>0</sub>, respectively.</p><p>Delta TMP was inversely correlated with hemoconcentration (p&#x0003c;0.001, Spearman r = -0.68), whereas no relation was seen with anti-Xa level or ETP at 240 min (<xref rid="pone.0128634.g003" ref-type="fig">Fig 3</xref>).</p><fig id="pone.0128634.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128634.g003</object-id><label>Fig 3</label><caption><title>Delta transmembrane pressure (TMP) in relation to hemoconcentration (BVS), anti-Xa-activity and endogenous thrombin potential (ETP).</title><p>Delta TMP is inversely correlated with hemoconcentration (p&#x0003c;0.0001, Spearman r = -0.68), no significant correlation between delta TMP and anti-Xa level or ETP at 240 min.</p></caption><graphic xlink:href="pone.0128634.g003"/></fig></sec><sec id="sec025"><title>Other pressures</title><p>No significant differences were observed in inlet or outlet line pressures or in prefilter pressure between the three schedules (<xref rid="pone.0128634.s005" ref-type="supplementary-material">S5 Fig</xref>).</p></sec></sec><sec id="sec026"><title>Parameters related to dialysis adequacy</title><sec id="sec027"><title>Reduction ratio (RR)</title><p>RR of urea after 240 min was 77.5 (76.0&#x02013;81.1), 78.9 (73.8&#x02013;81.9) and 77.5 (73.6&#x02013;85.1), with IN<sub>0</sub>, IN<sub>5</sub> and OUT<sub>0</sub> respectively, being slightly lower with IN<sub>0</sub> compared to IN<sub>5</sub> (p = 0.013). For the other time points no differences were noted between the three schedules (<xref rid="pone.0128634.s006" ref-type="supplementary-material">S1 Table</xref>).</p><p>RR of beta2microglobulin after 240 min was 82.1 (74.2&#x02013;84.9), 80.8 (76.5&#x02013;84.7) and 81.7 (75.9&#x02013;85.6) with IN<sub>0</sub>, IN<sub>5</sub> and OUT<sub>0</sub> respectively. No differences in RR of beta2microglobulin between the schedules were observed (<xref rid="pone.0128634.s006" ref-type="supplementary-material">S1 Table</xref>).</p></sec><sec id="sec028"><title>Relation between clotting parameters and dialysis efficiency</title><p>As illustrated in <xref rid="pone.0128634.g004" ref-type="fig">Fig 4</xref>, RR of urea and beta2microglobulin at 240 min were lower in sessions with an anti-Xa activity at 240 min below 0.3 IU/mL vs. equal or above 0.3 IU/mL: 0.76 (0.69&#x02013;0.80) vs. 0.84 (0.78&#x02013;0.86) and 0.76 (0.74&#x02013;0.80) vs. 0.85 (0.84&#x02013;0.88), respectively (p&#x0003c;0.001).</p><fig id="pone.0128634.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0128634.g004</object-id><label>Fig 4</label><caption><title>Reduction ratio of urea and beta2microglobulin in relation to anti-Xa activity and ETP.</title><p>Reduction ratio (RR) of urea (unfilled triangles) and beta2microglobulin (BETA2M) (filled triangles) in sessions with anti-Xa activity above or equal vs. below 0.3 IU/mL and detectable (ETP &#x0003e; 0) vs undetectable ETP (ETP = 0) at 240 min. Comparison between groups: * p&#x0003c;0.001.</p></caption><graphic xlink:href="pone.0128634.g004"/></fig><p>RR of urea and beta2microglobulin were also lower in patients with detectable ETP compared to patients with undetectable ETP at the end of the session: 0.75 (0.69&#x02013;0.78) vs. 0.83 (0.78&#x02013;0.86) and 0.76 (0.74&#x02013;0.79) vs. 0.85 (0.83&#x02013;0.87), respectively (p&#x0003c;0.001).</p><p>No relation was observed between visual clotting score and RR of neither urea nor beta2microglobulin.</p></sec></sec></sec><sec sec-type="conclusions" id="sec029"><title>Discussion</title><p>In the present study we found that administration of tinzaparin at the inlet blood line before the start of the session (IN<sub>0</sub>) resulted in lower anti-Xa activity and higher thrombin generation compared to administration at the outlet line (OUT<sub>0</sub>) or administration 5 min after start of the session (IN<sub>5</sub>). Anti-Xa levels below 0.3 IU/mL at the end of postdilution hemodiafiltration sessions were associated with more thrombin generation, worse visual clotting score and lower RR for urea and beta2microglobulin.</p><p>Although advised by experts [<xref rid="pone.0128634.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0128634.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0128634.ref005" ref-type="bibr">5</xref>], administration at the outlet line is, at least based on literature data, rarely applied [<xref rid="pone.0128634.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0128634.ref007" ref-type="bibr">7</xref>]. In most studies LMWHs are injected at the inlet line [<xref rid="pone.0128634.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0128634.ref020" ref-type="bibr">20</xref>] or the administration site is not specified [<xref rid="pone.0128634.ref021" ref-type="bibr">21</xref>&#x02013;<xref rid="pone.0128634.ref024" ref-type="bibr">24</xref>]. In the information leaflet of tinzaparin, enoxaparin and nadroparin, administration via the arterial line is recommended [<xref rid="pone.0128634.ref025" ref-type="bibr">25</xref>], whereas in guidelines no recommendation concerning the administration site is provided [<xref rid="pone.0128634.ref001" ref-type="bibr">1</xref>].</p><p>However, in spite of the currently frequent use of high-flux membranes and hemodiafiltration, the effect of administration route of LMWHs has, to the best of our knowledge, never been studied systematically. With low-flux membranes, Vanuytsel et al. found no differences in anti-Xa activity after administration of nadroparin either at the inlet or outlet line [<xref rid="pone.0128634.ref026" ref-type="bibr">26</xref>].</p><p>Tinzaparin has compared to other LMWHs the longest chains. Hence, it is very likely that when using LMWHs with shorter chains such as enoxaparin and nadroparin, removal will likewise occur or even be more pronounced. The removal of enoxaparin during hemodiafiltration has previously been demonstrated, however without assessing the impact of the administration site [<xref rid="pone.0128634.ref027" ref-type="bibr">27</xref>].</p><p>We ascribe the lower anti-Xa observed in the IN<sub>0</sub> schedule, to dialytic/convective removal of unbound tinzaparin from the rinsing solution through a yet uncoated dialyzer membrane. Also enhanced adsorption to the uncoated membrane could play a role. Alternatively, the lower anti-Xa levels with IN<sub>0</sub> could simply be the logical consequence of 5 min earlier administration compared to the IN<sub>5</sub> schedule. A simulation based on kinetic parameters, however resulted in a difference of barely 0.01 IU/mL anti-Xa activity at the end of dialysis with 5 min difference in administration time, whereas the difference that was observed here was in the range of 0.1 IU/mL. Hence the role of such small difference in time as applied here is probably negligible.</p><p>In addition to anti-Xa, thrombin generation was assessed by ETP determination. Thrombin generation assays measure the ability of plasma to generate thrombin following ex vivo activation of coagulation with tissue factor [<xref rid="pone.0128634.ref028" ref-type="bibr">28</xref>]. Hence, not only the initiation phase, but also the propagation and terminal phase of clotting are measured; ETP reflects the potential thrombin forming capacity. As the ultimate goal of anticoagulation during dialysis is the prevention of clot formation, measurement of ETP is highly informative. We found that anti-Xa activity of 0.3 IU/mL was able to discriminate for measurable ETP. When comparing the different routes of administration, higher ETP was observed with IN<sub>0</sub> compared to IN<sub>5</sub> and OUT<sub>0</sub>.</p><p>In healthy controls, ETP was found to be a valuable test for measuring the anticoagulant effect of heparins [<xref rid="pone.0128634.ref029" ref-type="bibr">29</xref>]. Only limited data on thrombin generation assays in hemodialysis are available. Predialysis ETP values were found either lower [<xref rid="pone.0128634.ref030" ref-type="bibr">30</xref>] or higher [<xref rid="pone.0128634.ref031" ref-type="bibr">31</xref>] compared to healthy controls. Vernom et al. found a decreased postdialysis ETP compared to predialysis values [<xref rid="pone.0128634.ref006" ref-type="bibr">6</xref>]. In contrast to our data, however, they consistently demonstrated thrombin generation in postdialysis samples. This could be attributed to the lower tinzaparin doses used in their patients, compared to ours.</p><p>In addition to coagulation parameters, we also evaluated dialysis performance by calculating the RR of urea and beta2microglobulin. If fibers occlude, it is expected that RR of uremic retention solutes will be lower. In the present study however, no clinically important differences in RR were observed between the three administration schedules.</p><p>Interestingly, but initially not defined as study outcome, we noticed lower RR of both urea and beta2microglobulin in sessions ending with an anti-Xa activity below 0.3 IU/mL. Also in sessions with detectable ETP, a lower RR of these uremic retention solutes was observed. To the best of our knowledge we are the first to study the anticoagulant effect of LMWH during hemodiafiltration by measuring RR in relation to anti-Xa and ETP.</p><p>No differences in visual clotting score were noted between the three administration schedules. A limitation of the present study is the fact that the investigators rating the visual clotting score were not blinded to the injection mode.</p><p>In conclusion, the injection of tinzaparin, and by extrapolation probably of all LMWHs with a MW smaller than or equal to that of tinzaparin, at the blood inlet line before the start of hemodiafiltration is associated with loss of anticoagulant activity. This procedure although widely applied cannot be recommended as it associated with washing away of expensive medication. Injection of LMWH at the outlet line or in the inlet line after 5 min are better alternatives.</p><p>In postdilution volume controlled hemodiafiltration, with an exchange volume of 25% of blood flow and anticoagulated with tinzaparin, an anti-Xa activity below 0.3 IU/mL at the end of a 4 hour session, is associated with thrombin generation, a higher clotting score and a decreased RR of urea and beta2microglobulin. Based on these results, it can be hypothesized that if tinzaparin dose is targeted to a level slightly above 0.3 IU/mL at the end of the session, not only improved dialysis efficiency is obtained but in addition overdosing of LMWH will be avoided. These data need however confirmation from a larger sample sized study in which patients are injected with various doses of tinzaparin, in order to obtain anti-Xa activity around 0.3 IU/ml at the end of the session.</p></sec><sec sec-type="supplementary-material" id="sec030"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0128634.s001"><label>S1 Fig</label><caption><title>Tinzaparin dose in relation to body weight and anti-Xa activity in relation to dose per kg body weight.</title><p>(TIF)</p></caption><media xlink:href="pone.0128634.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128634.s002"><label>S2 Fig</label><caption><title>Median anti-Xa activity (IU/mL) measured at different time points.</title><p>Full bars: IN<sub>0</sub>, open bars: IN5 and hatched bars: OUT<sub>0</sub>. *: p&#x0003c;0.05 vs. IN<sub>0</sub>.</p><p>(TIF)</p></caption><media xlink:href="pone.0128634.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128634.s003"><label>S3 Fig</label><caption><title>Visual clotting scores of membrane, bubble trap and expansion chamber.</title><p>(TIF)</p></caption><media xlink:href="pone.0128634.s003.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128634.s004"><label>S4 Fig</label><caption><title>Visual clotting scores of membrane, bubble trap and expansion chamber in relation to anti-Xa activity (IU/mL) measured at 240 min.</title><p>(TIF)</p></caption><media xlink:href="pone.0128634.s004.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128634.s005"><label>S5 Fig</label><caption><title>Evolution of pressure during the sessions.</title><p>Open squares and full lines: IN<sub>0</sub>, full squares and datched lines: IN<sub>5</sub>, open triangles and full lines: OUT<sub>0</sub>.</p><p>(TIF)</p></caption><media xlink:href="pone.0128634.s005.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128634.s006"><label>S1 Table</label><caption><title>Reduction ratio (RR) of urea and beta2microglobulin (Beta2M): median and interquartile range.</title><p>(DOCX)</p></caption><media xlink:href="pone.0128634.s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128634.s007"><label>S1 Text</label><caption><title>Protocol English version.</title><p>(DOC)</p></caption><media xlink:href="pone.0128634.s007.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128634.s008"><label>S2 Text</label><caption><title>Protocol Dutch version.</title><p>(DOC)</p></caption><media xlink:href="pone.0128634.s008.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0128634.s009"><label>S3 Text</label><caption><title>CONSORT checklist.</title><p>(DOC)</p></caption><media xlink:href="pone.0128634.s009.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0128634.ref001"><label>1</label><mixed-citation publication-type="journal">
<collab>Working group European Best Practise Guidelines</collab> (<year>2002</year>) <article-title>Section V: Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system</article-title>. <source>Nephrol Dial Transplant</source>
<volume>17</volume>(<issue>suppl 7</issue>): <fpage>64</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">11773464</pub-id></mixed-citation></ref><ref id="pone.0128634.ref002"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Davenport</surname><given-names>A</given-names></name> (<year>2009</year>) <article-title>Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments</article-title>. <source>Nephrology</source>
<volume>14</volume>: <fpage>455</fpage>&#x02013;<lpage>461</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1440-1797.2009.01135.x">10.1111/j.1440-1797.2009.01135.x</ext-link></comment>
<pub-id pub-id-type="pmid">19674314</pub-id></mixed-citation></ref><ref id="pone.0128634.ref003"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Devreese</surname><given-names>K</given-names></name>, <name><surname>Wijns</surname><given-names>W</given-names></name>, <name><surname>Combes</surname><given-names>I</given-names></name>, <name><surname>Van kerckhoven</surname><given-names>S</given-names></name>, <name><surname>Hoylaerts</surname><given-names>MF</given-names></name> (<year>2007</year>) <article-title>Thrombin generation in plasma of healthy adults and children: chromogenic versus fluorogenic thrombogram analysis</article-title>. <source>Thromb and Haemost</source>
<volume>98</volume>: <fpage>600</fpage>&#x02013;<lpage>613</lpage>.
<pub-id pub-id-type="pmid">17849049</pub-id></mixed-citation></ref><ref id="pone.0128634.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Davenport</surname><given-names>A</given-names></name> (<year>2011</year>) <article-title>What are the anticoagulation options for intermittent hemodialysis?</article-title>
<source>Nat Rev Nephrol</source>
<volume>7</volume>: <fpage>499</fpage>&#x02013;<lpage>508</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrneph.2011.88">10.1038/nrneph.2011.88</ext-link></comment>
<pub-id pub-id-type="pmid">21727925</pub-id></mixed-citation></ref><ref id="pone.0128634.ref005"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Davenport</surname><given-names>A</given-names></name> (<year>2008</year>) <article-title>Low-molecular-weight heparin for routine hemodialysis</article-title>. <source>Hemodial Int</source>
<volume>12</volume>: <fpage>S34</fpage>&#x02013;<lpage>S37</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1542-4758.2008.00322.x">10.1111/j.1542-4758.2008.00322.x</ext-link></comment>
<pub-id pub-id-type="pmid">18837768</pub-id></mixed-citation></ref><ref id="pone.0128634.ref006"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Vernon</surname><given-names>K</given-names></name>, <name><surname>Peasegood</surname><given-names>J</given-names></name>, <name><surname>Riddell</surname><given-names>A</given-names></name>, <name><surname>Davenport</surname><given-names>A</given-names></name> (<year>2011</year>) <article-title>Dialyzers designed to increase internal filtration do not result in significantly increased platelet activation and thrombin generation</article-title>. <source>Nephron Clin Pract</source>
<volume>117</volume>: <fpage>c403</fpage>&#x02013;<lpage>c408</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000319884">10.1159/000319884</ext-link></comment>
<pub-id pub-id-type="pmid">21071966</pub-id></mixed-citation></ref><ref id="pone.0128634.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Pauwels</surname><given-names>R</given-names></name>, <name><surname>Devreese</surname><given-names>K</given-names></name>, <name><surname>Van Biesen</surname><given-names>W</given-names></name>, <name><surname>Eloot</surname><given-names>S</given-names></name>, <name><surname>Glorieux</surname><given-names>G</given-names></name>, <name><surname>Vanholder</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Bedside monitoring of anticoagulation in chronic haemodialysis patients treated with tinzaparin</article-title>. <source>Nephrol Dial Transplant</source>
<volume>29</volume>: <fpage>1092</fpage>&#x02013;<lpage>1096</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ndt/gft508">10.1093/ndt/gft508</ext-link></comment>
<pub-id pub-id-type="pmid">24366900</pub-id></mixed-citation></ref><ref id="pone.0128634.ref008"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Egfjord</surname><given-names>M</given-names></name>, <name><surname>Rosenlund</surname><given-names>L</given-names></name>, <name><surname>Hedegaard</surname><given-names>B</given-names></name>, <name><surname>Buchardt</surname><given-names>HL</given-names></name>, <name><surname>Stengel</surname><given-names>C</given-names></name>, <name><surname>Gardar</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>1998</year>) <article-title>Dose titration study of tinzaparin, a low molecular weight heparin, in patients on chronic hemodialysis</article-title>. <source>Artif Organs</source>
<volume>22</volume>: <fpage>633</fpage>&#x02013;<lpage>637</lpage>.
<pub-id pub-id-type="pmid">9702313</pub-id></mixed-citation></ref><ref id="pone.0128634.ref009"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Lai</surname><given-names>KN</given-names></name>, <name><surname>Ho</surname><given-names>K</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Szeto</surname><given-names>CC</given-names></name> (<year>1998</year>) <article-title>Use of single dose low-molecular-weight heparin in long hemodialisis</article-title>. <source>Int J Artif Organs</source>
<volume>21</volume>: <fpage>196</fpage>&#x02013;<lpage>200</lpage>.
<pub-id pub-id-type="pmid">9649059</pub-id></mixed-citation></ref><ref id="pone.0128634.ref010"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Badawi</surname><given-names>L</given-names></name>, <name><surname>Akeel</surname><given-names>N</given-names></name>, <name><surname>Shaheen</surname><given-names>FA</given-names></name>, <name><surname>Al Ahmadi</surname><given-names>S</given-names></name> (<year>2005</year>) <article-title>Dose and lipid lowering effect of tinzaparin sodium: a single center experience</article-title>. <source>Saudi J Kidney Dis Transplant</source>
<volume>16</volume>: <fpage>161</fpage>&#x02013;<lpage>165</lpage>.
<pub-id pub-id-type="pmid">18202492</pub-id></mixed-citation></ref><ref id="pone.0128634.ref011"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Bramham</surname><given-names>K</given-names></name>, <name><surname>Varrier</surname><given-names>M</given-names></name>, <name><surname>Asgari</surname><given-names>E</given-names></name>, <name><surname>Makanjuola</surname><given-names>D</given-names></name> (<year>2008</year>): <article-title>Comparison of Tinzaparin and Unfractionated Heparin as Anticoagulation on Haemodialysis: Equal Safety, Efficacy and Economical Parity</article-title>. <source>Nephron Clin Pract</source>
<volume>110</volume>: <fpage>c107</fpage>&#x02013;<lpage>c113</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000158561">10.1159/000158561</ext-link></comment>
<pub-id pub-id-type="pmid">18824874</pub-id></mixed-citation></ref><ref id="pone.0128634.ref012"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Simpson</surname><given-names>HK</given-names></name>, <name><surname>Baird</surname><given-names>J</given-names></name>, <name><surname>Allison</surname><given-names>M</given-names></name>, <name><surname>Briggs</surname><given-names>JD</given-names></name>, <name><surname>Rowe</surname><given-names>PA</given-names></name>, <name><surname>Welsh</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>Long-term use of the low molecular weight heparin tinzaparin in haemodialysis</article-title>. <source>Haemostasis</source>
<volume>26</volume>: <fpage>90</fpage>&#x02013;<lpage>97</lpage>.
<pub-id pub-id-type="pmid">9119288</pub-id></mixed-citation></ref><ref id="pone.0128634.ref013"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Sabry</surname><given-names>A</given-names></name>, <name><surname>Taha</surname><given-names>M</given-names></name>, <name><surname>Nada</surname><given-names>M</given-names></name>, <name><surname>Al Fawzan</surname><given-names>F</given-names></name>, <name><surname>Alsaran</surname><given-names>K</given-names></name> (<year>2009</year>) <article-title>Anticoagulation therapy during haemodialysis: a comparative study between two heparin regimens</article-title>. <source>Blood Coagul Fibrinolysis</source>
<volume>20</volume>: <fpage>57</fpage>&#x02013;<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/MBC.0b013e32831bec0f">10.1097/MBC.0b013e32831bec0f</ext-link></comment>
<pub-id pub-id-type="pmid">20523166</pub-id></mixed-citation></ref><ref id="pone.0128634.ref014"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Malyszko</surname><given-names>J</given-names></name>, <name><surname>Malyszko</surname><given-names>JS</given-names></name>, <name><surname>Hryszko</surname><given-names>T</given-names></name>, <name><surname>Pawlak</surname><given-names>K</given-names></name>, <name><surname>Mysliwiec</surname><given-names>M</given-names></name> (<year>2004</year>) <article-title>Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients</article-title>. <source>Am J Nephrol</source>
<volume>24</volume>: <fpage>624</fpage>&#x02013;<lpage>629</lpage>.
<pub-id pub-id-type="pmid">15627717</pub-id></mixed-citation></ref><ref id="pone.0128634.ref015"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Saltissi</surname><given-names>D</given-names></name>, <name><surname>Morgan</surname><given-names>C</given-names></name>, <name><surname>Westhuyzen</surname><given-names>J</given-names></name>, <name><surname>Healy</surname><given-names>H</given-names></name> (<year>1999</year>) <article-title>Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation</article-title>. <source>Nephrol Dial Transplant</source>
<volume>14</volume>:<fpage>2698</fpage>&#x02013;<lpage>2703</lpage>.
<pub-id pub-id-type="pmid">10534515</pub-id></mixed-citation></ref><ref id="pone.0128634.ref016"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Sagedal</surname><given-names>S</given-names></name>, <name><surname>Hartmann</surname><given-names>A</given-names></name>, <name><surname>Sundstr&#x000f8;m</surname><given-names>K</given-names></name>, <name><surname>Bj&#x000f8;rnsen</surname><given-names>S</given-names></name>, <name><surname>Fauchald</surname><given-names>P</given-names></name>, <name><surname>Brosstad</surname><given-names>F</given-names></name> (<year>1999</year>) <article-title>A single dose of dalteparin effectively prevents clotting during haemodialysis</article-title>. <source>Nephrol Dial Transplant</source>
<volume>14</volume>:<fpage>1943</fpage>&#x02013;<lpage>1947</lpage>.
<pub-id pub-id-type="pmid">10462275</pub-id></mixed-citation></ref><ref id="pone.0128634.ref017"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Guillet</surname><given-names>B</given-names></name>, <name><surname>Simon</surname><given-names>N</given-names></name>, <name><surname>Sampol</surname><given-names>JJ</given-names></name>, <name><surname>Lorec-Penet</surname><given-names>AM</given-names></name>, <name><surname>Portugal</surname><given-names>H</given-names></name>, <name><surname>Berland</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis</article-title>. <source>Nephrol Dial Transplant</source>
<volume>18</volume>: <fpage>2348</fpage>&#x02013;<lpage>2353</lpage>.
<pub-id pub-id-type="pmid">14551364</pub-id></mixed-citation></ref><ref id="pone.0128634.ref018"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Lim</surname><given-names>W</given-names></name>, <name><surname>Cook</surname><given-names>DJ</given-names></name>, <name><surname>Crowther</surname><given-names>MA</given-names></name> (<year>2004</year>) <article-title>Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials</article-title>. <source>J Am Soc Nephrol</source>
<volume>15</volume>: <fpage>3192</fpage>&#x02013;<lpage>3206</lpage>.
<pub-id pub-id-type="pmid">15579523</pub-id></mixed-citation></ref><ref id="pone.0128634.ref019"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Sridharan</surname><given-names>S</given-names></name>, <name><surname>Berdeprado</surname><given-names>J</given-names></name>, <name><surname>Sivalingam</surname><given-names>M</given-names></name>, <name><surname>Farrington</surname><given-names>K</given-names></name> (<year>2012</year>) <article-title>Dalteparin Dosing in High-Flux Haemodialysis and Haemodiafiltration</article-title>. <source>Nephron Clin Pract</source>
<volume>122</volume>: <fpage>53</fpage>&#x02013;<lpage>57</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000348830">10.1159/000348830</ext-link></comment>
<pub-id pub-id-type="pmid">23548465</pub-id></mixed-citation></ref><ref id="pone.0128634.ref020"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Kirwan</surname><given-names>CJ</given-names></name>, <name><surname>Baig</surname><given-names>ZF</given-names></name>, <name><surname>Platton</surname><given-names>S</given-names></name>, <name><surname>MacCullum</surname><given-names>PK</given-names></name>, <name><surname>Ashman</surname><given-names>N</given-names></name> (<year>2013</year>) <article-title>Anti-Xa activity supports using a simple dosing algorithm for tinzaparin for anticoagulation in hemodialysis</article-title>. <source>Nephron Clin Pract</source>
<volume>123</volume>: <fpage>7</fpage>&#x02013;<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1159/000351047">10.1159/000351047</ext-link></comment>
<pub-id pub-id-type="pmid">23751953</pub-id></mixed-citation></ref><ref id="pone.0128634.ref021"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Krummel</surname><given-names>T</given-names></name>, <name><surname>Scheidt</surname><given-names>E</given-names></name>, <name><surname>Borni-Duval</surname><given-names>C</given-names></name>, <name><surname>Bazin</surname><given-names>D</given-names></name>, <name><surname>Lefebvre</surname><given-names>F</given-names></name>, <name><surname>Nguyen</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Haemodialysis in patients treated with oral anticoagulant: should we heparinize?</article-title>
<source>Nephrol Dial Transplant</source>
<volume>29</volume>: <fpage>906</fpage>&#x02013;<lpage>913</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ndt/gft522">10.1093/ndt/gft522</ext-link></comment>
<pub-id pub-id-type="pmid">24459138</pub-id></mixed-citation></ref><ref id="pone.0128634.ref022"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Schrader</surname><given-names>J</given-names></name>, <name><surname>Valentin</surname><given-names>R</given-names></name>, <name><surname>Tonnis</surname><given-names>HJ</given-names></name>, <name><surname>Hildebrand</surname><given-names>U</given-names></name>, <name><surname>Stibbe</surname><given-names>W</given-names></name>, <name><surname>Armstrong</surname><given-names>V</given-names></name>, <etal>et al</etal> (<year>1985</year>) <article-title>Low molecular weight heparin in hemodialysis and hemofiltration patients</article-title>. <source>Kidney Int</source>
<volume>28</volume>: <fpage>823</fpage>&#x02013;<lpage>829</lpage>.
<pub-id pub-id-type="pmid">3936965</pub-id></mixed-citation></ref><ref id="pone.0128634.ref023"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Klingel</surname><given-names>R</given-names></name>, <name><surname>Schwarting</surname><given-names>A</given-names></name>, <name><surname>Lotz</surname><given-names>J</given-names></name>, <name><surname>Eckert</surname><given-names>M</given-names></name>, <name><surname>Hohmann</surname><given-names>V</given-names></name>, <name><surname>Hafner</surname><given-names>G</given-names></name> (<year>2004</year>) <article-title>Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study</article-title>. <source>Kidney Blood Press Res</source>
<volume>27</volume>: <fpage>211</fpage>&#x02013;<lpage>217</lpage>.
<pub-id pub-id-type="pmid">15273423</pub-id></mixed-citation></ref><ref id="pone.0128634.ref024"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Sabovic</surname><given-names>M</given-names></name>, <name><surname>Salobir</surname><given-names>B</given-names></name>, <name><surname>Preloznik Zupan</surname><given-names>I</given-names></name>, <name><surname>Bratina</surname><given-names>P</given-names></name>, <name><surname>Bojec</surname><given-names>V</given-names></name>, <name><surname>Buturovic Ponikvar</surname><given-names>J</given-names></name> (<year>2005</year>) <article-title>The influence of the haemodialysis procedure on platelets, coagulation and fibrinolysis</article-title>. <source>Pathophysiol Haemost Thromb</source>
<volume>34</volume>: <fpage>274</fpage>&#x02013;<lpage>278</lpage>.
<pub-id pub-id-type="pmid">16772739</pub-id></mixed-citation></ref><ref id="pone.0128634.ref025"><label>25</label><mixed-citation publication-type="other">Belgisch centrum voor farmacotherapeutische informatie. Available: <ext-link ext-link-type="uri" xlink:href="http://www.bcfi.be/GGR/Index.cfm?ggrWelk=/nIndex/GGR/Merk/MP_I.cfm">http://www.bcfi.be/GGR/Index.cfm?ggrWelk=/nIndex/GGR/Merk/MP_I.cfm</ext-link>. Accessed 19 December 2014.</mixed-citation></ref><ref id="pone.0128634.ref026"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Vanuytsel</surname><given-names>JL</given-names></name>, <name><surname>Lins</surname><given-names>RL</given-names></name>, <name><surname>Zachee</surname><given-names>P</given-names></name>, <name><surname>Matteeusen</surname><given-names>J</given-names></name>, <name><surname>Hosten</surname><given-names>S</given-names></name>, <name><surname>Lens</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Comparison of different routes of administration of nadroparin in hemodialysis</article-title>. <source>Clin Nephrol</source>
<volume>52</volume>: <fpage>322</fpage>&#x02013;<lpage>325</lpage>.
<pub-id pub-id-type="pmid">10584996</pub-id></mixed-citation></ref><ref id="pone.0128634.ref027"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Sombolos</surname><given-names>KI</given-names></name>, <name><surname>Fragia</surname><given-names>TK</given-names></name>, <name><surname>Gionanlis</surname><given-names>LC</given-names></name>, <name><surname>Veneti</surname><given-names>PE</given-names></name>, <name><surname>Bamichas</surname><given-names>GI</given-names></name>, <name><surname>Frachidis</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>The anticoagulant activity of enoxaparin sodium during on-line hemodiafiltration and conventional hemodialysis</article-title>. <source>Hemodial Int</source>
<volume>13</volume>: <fpage>43</fpage>&#x02013;<lpage>47</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1542-4758.2009.00336.x">10.1111/j.1542-4758.2009.00336.x</ext-link></comment>
<pub-id pub-id-type="pmid">19210277</pub-id></mixed-citation></ref><ref id="pone.0128634.ref028"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Hemker</surname><given-names>HC</given-names></name>, <name><surname>Giesen</surname><given-names>P</given-names></name>, <name><surname>Al Dieri</surname><given-names>R</given-names></name>, <name><surname>Regnault</surname><given-names>V</given-names></name>, <name><surname>de Smedt</surname><given-names>E</given-names></name>, <name><surname>Wagenvoord</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Calibrated automated thrombin generation measurement in clotting plasma</article-title>. <source>Pathophysiol Haemost Thromb</source>
<volume>33</volume>: <fpage>4</fpage>&#x02013;<lpage>15</lpage>.
<pub-id pub-id-type="pmid">12853707</pub-id></mixed-citation></ref><ref id="pone.0128634.ref029"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Al Dieri</surname><given-names>R</given-names></name>, <name><surname>Alban</surname><given-names>S</given-names></name>, <name><surname>Beguin</surname><given-names>S</given-names></name>, <name><surname>Coenraad Hemker</surname><given-names>H</given-names></name> (<year>2004</year>) <article-title>Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time</article-title>. <source>J Thromb Haemost</source>
<volume>2</volume>: <fpage>1395</fpage>&#x02013;<lpage>1401</lpage>.
<pub-id pub-id-type="pmid">15304046</pub-id></mixed-citation></ref><ref id="pone.0128634.ref030"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Jeong</surname><given-names>JC</given-names></name>, <name><surname>Kim</surname><given-names>J-E</given-names></name>, <name><surname>Ryu</surname><given-names>JW</given-names></name>, <name><surname>Joo</surname><given-names>KW</given-names></name>, <name><surname>Kim</surname><given-names>HK</given-names></name> (<year>2013</year>) <article-title>Plasma haemostatic potential of haemodialysis patients assessed by thrombin generation assay: Hypercoagulability in patients with vascular access thrombosis</article-title>. <source>Thromb Res</source>
<volume>132</volume>: <fpage>604</fpage>&#x02013;<lpage>609</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.thromres.2013.09.002">10.1016/j.thromres.2013.09.002</ext-link></comment>
<pub-id pub-id-type="pmid">24060191</pub-id></mixed-citation></ref><ref id="pone.0128634.ref031"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Burton</surname><given-names>JO</given-names></name>, <name><surname>Hamali</surname><given-names>HA</given-names></name>, <name><surname>Singh</surname><given-names>R</given-names></name>, <name><surname>Abbasian</surname><given-names>N</given-names></name>, <name><surname>Parsons</surname><given-names>R</given-names></name>, <name><surname>Patel</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Elevated Levels of Procoagulant Plasma Microvesicles in Dialysis Patients</article-title>. <source>PloS one</source>
<volume>8</volume>:<fpage>e 72663</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0072663">10.1371/journal.pone.0072663</ext-link></comment>
<pub-id pub-id-type="pmid">23936542</pub-id></mixed-citation></ref></ref-list></back></article>